Cullen Frost Bankers Inc. increased its stake in CVS Health Corporation (NYSE:CVS) by 0.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 225,452 shares of the pharmacy operator’s stock after buying an additional 1,557 shares during the period. Cullen Frost Bankers Inc.’s holdings in CVS Health Corporation were worth $21,584,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Springbok Capital Management LLC increased its position in CVS Health Corporation by 190.5% in the first quarter. Springbok Capital Management LLC now owns 1,130 shares of the pharmacy operator’s stock worth $117,000 after buying an additional 741 shares in the last quarter. Arcadia Investment Management Corp MI increased its position in CVS Health Corporation by 87.7% in the second quarter. Arcadia Investment Management Corp MI now owns 1,605 shares of the pharmacy operator’s stock worth $154,000 after buying an additional 750 shares in the last quarter. Physicians Financial Services Inc. increased its position in CVS Health Corporation by 5.8% in the second quarter. Physicians Financial Services Inc. now owns 1,849 shares of the pharmacy operator’s stock worth $177,000 after buying an additional 101 shares in the last quarter. Highland Private Wealth Management acquired a new position in CVS Health Corporation during the first quarter worth about $198,000. Finally, Integrated Investment Consultants LLC increased its position in CVS Health Corporation by 13.8% in the second quarter. Integrated Investment Consultants LLC now owns 2,311 shares of the pharmacy operator’s stock worth $221,000 after buying an additional 280 shares in the last quarter. Institutional investors and hedge funds own 80.96% of the company’s stock.
Shares of CVS Health Corporation (NYSE:CVS) traded down 0.10% during trading on Friday, hitting $86.40. 4,346,345 shares of the stock traded hands. The company’s 50 day moving average is $91.41 and its 200 day moving average is $96.91. The firm has a market cap of $92.12 billion, a PE ratio of 19.88 and a beta of 0.83. CVS Health Corporation has a 52-week low of $85.89 and a 52-week high of $106.67.
CVS Health Corporation (NYSE:CVS) last announced its earnings results on Tuesday, August 2nd. The pharmacy operator reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. The company earned $43.70 billion during the quarter, compared to analysts’ expectations of $44.28 billion. CVS Health Corporation had a net margin of 2.88% and a return on equity of 15.86%. The firm’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.19 earnings per share. On average, equities research analysts predict that CVS Health Corporation will post $5.86 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 3rd. Shareholders of record on Monday, October 24th will be given a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date of this dividend is Thursday, October 20th. CVS Health Corporation’s payout ratio is currently 39.08%.
A number of research analysts recently issued reports on CVS shares. Argus restated a “buy” rating and set a $120.00 target price on shares of CVS Health Corporation in a research report on Thursday, August 4th. Mizuho boosted their target price on shares of CVS Health Corporation from $108.00 to $111.00 and gave the company a “buy” rating in a research report on Thursday, August 4th. Leerink Swann restated a “buy” rating on shares of CVS Health Corporation in a research report on Wednesday, August 3rd. Jefferies Group restated a “buy” rating on shares of CVS Health Corporation in a research report on Monday, July 4th. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $115.00 price objective on shares of CVS Health Corporation in a research report on Tuesday, September 20th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $112.11.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS).
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.